Rezdiffra Pregnancy and Lactation Registry
← catalyst calendarNCT07541469 · readout in 1,328 d
Sponsored by Madrigal Pharmaceuticals, Inc. (industry) · MDGL — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
10estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-04 | actual | When the study began enrolling |
| Primary completion | 2030-04-08 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-04-08 | estimated | The whole study's end, after follow-up |
| First posted | 2026-04-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- MASH - Metabolic Dysfunction-Associated Steatohepatitis
Intervention
- Drug: Rezdiffra
Primary outcome
what the primary-completion date above is the date OFPregnancy and Infant Outcomes Among Women Exposed to Rezdiffra During Pregnancy and/or Lactation
measured From enrollment through pregnancy and up to 12 months of infant age (participant observational period up to approximately 21 months)
Permalink · MDGL's whole pipeline · Catalyst calendar · Every registered study · What changed